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Abstract
Background: Inflammatory bowel disease, comprising Crohn’s disease and ulcerative colitis, is a life-long currently
incurable illness. It causes bouts of acute intestinal inflammation, in an unpredictable relapsing-remitting course,
with bloody diarrhoea and extreme urgency to access a toilet. Faecal incontinence is a devastating social and
hygiene problem, impacting heavily on quality of life and ability to work and socialise. Faecal incontinence affects 2–10 %
of adults in the general population. People with inflammatory bowel disease have a high risk of incontinence with up to
74 % affected. No previous study has explored conservative interventions for these patients.
Methods: This randomised controlled trial will recruit 186 participants to answer the research question: does
implementation of the UK nationally recommended guidance approach to stepwise management of faecal
incontinence improve bowel control and quality of life in people with inflammatory bowel disease? We have
worked with people with inflammatory bowel disease to translate this guidance into a condition-specific
information booklet on managing incontinence. We will randomise participants to receive the booklet, or the
booklet plus up to four 30-minute sessions with an inflammatory bowel disease specialist nurse. To be
eligible, patients must be in disease remission and report incontinence. The primary outcome measure at 6
months after randomisation is the St Mark’s incontinence score. Other outcomes include quality of life, MY-MOP
(generic tool: participants set two goals for intervention, grading goals at baseline and then re-scoring after
intervention) and EQ-5D-5 L to enable calculation of quality-adjusted life years. Analysis will be on an intention-to-treat
basis. Qualitative interviews will explore participant and health professionals’ views on the interventions.
Discussion: Few high-quality studies of conservative interventions in inflammatory bowel disease, and none for faecal
incontinence, have been conducted. We have collaborated with patients to design this study. Blinding to this
behavioural intervention is not possible, but our self-report outcome measures with a degree of objectivity. There is
genuine equipoise between the booklet only and booklet plus nurse arms, and the study will determine if additional
support from a nurse is a crucial element in implementing advice.
Trial registration: clinitrials.gov.uk: NCT02355834 (Date of registration: 12 December 2014).
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Background
Background and rationale
Inflammatory bowel disease (IBD, comprising mostly
Crohn’s disease and ulcerative colitis) is a life-long cur-
rently incurable disease affecting approximately 250,000
adults in the UK, 2.2 million in Europe and 1.4 million
in North America [1]. It causes bouts of acute intestinal
inflammation in an unpredictable relapsing-remitting
pattern, with bloody diarrhoea and extreme urgency to
access a toilet. Chronic diarrhoea, rectal inflammation
and reduced rectal capacity, disease or surgery which
affect the continence mechanism, and a fatigable anal
sphincter [2] all contribute to a high risk of faecal incon-
tinence (FI) [3].
FI is a devastating social and hygiene problem, impact-
ing heavily on quality of life and ability to work and so-
cialise, and affecting 2–10 % of adults in the general
population [4, 5]. Urgency and FI are accepted by both
patients and clinicians in IBD flare-up, but at least a
quarter of people with IBD also report extremely limit-
ing symptoms persisting in remission [3]. Some young
adults are completely housebound [6]. Interviews with
people with IBD-related FI (IBD-FI) describe multiple
life limitations: ‘the fear of being faecally incontinent has
a great impact on your life, and… this fear turns into
stress and anxiety, which make it more likely that you
will be incontinent… you enter a vicious cycle. It makes
you nervous about going out, using public transport, go-
ing on holiday, and having intimate relationships’ [6].
The imperative to find a toilet immediately is as limiting
as frank incontinence and is reported as happening daily
by 89 % of people with IBD during a disease flare and 66
% in remission [7]. Poor bowel control and the need for
urgent toilet access are among the top ten concerns of
people with IBD [8]. Some 81.3 % of people with IBD in
the UK worry about the availability of toilets whenever
they go somewhere new [7]. Crohn’s and Colitis UK (pa-
tient charity) have prioritised the issue of FI in IBD, fund-
ing studies on prevalence and quality of life [3],
experiences of IBD-FI [6], help-seeking [9], and develop-
ment of a patient-reported questionnaire for IBD-FI [10].
Previous work on FI in non-IBD populations has
found that 70–80 % cure and improvement is feasible.
Patients receiving conservative management in specialist
nurse services are highly satisfied with their improve-
ment and report improved ability to live with symptoms
and better quality of life [11–13]. IBD nurse specialists
are widespread in the UK National Health Service
(NHS) [14], are highly valued by patients, and view FI as
one of their core areas of practice [15]. However, our
qualitative and quantitative work [3, 6, 9] has found that
few IBD nurses offer any intervention specifically for FI.
Reasons for this are unclear, but informal discussions
suggest the primary barrier is lack of training for IBD
nurses in managing FI. Small studies have suggested
some benefit for individual specialist interventions for
IBD-FI but no comprehensive approach has been
evaluated.
The UK National Institute for Health and Clinical
Excellence (NICE) [13] recommends a step-wise interven-
tion algorithm for FI, starting with low-cost conservative
interventions such as diet and anti-diarrhoeal medication,
bowel retraining and pelvic floor exercises, estimating that
70 % of people with FI can be improved. There are several
Cochrane reviews finding that treatments are effective for
FI [12, 16, 17]. None has included people with IBD.
Co-author AE has found that 18/27 (66 %) IBD pa-
tients managed in a nurse-led FI service reported im-
proved continence and 63 % a significantly reduced
continence score (unpublished audit). In 218 patients
with radiation bowel disease (with similar symptoms)
it was found that nurse intervention improves FI and
quality of life and produces similar response to gastro-
enterologist intervention and is significantly better than a
booklet alone, with improvements sustained at 1 year [18].
Our specialist clinical experience suggests that people with
IBD are likely to respond well to the NICE algorithmic
approach.
Objectives
We aim to answer the research question “Does imple-
mentation of the UK nationally (NICE)-recommended
approach [13] to stepwise management of FI improve
bowel control and quality of life in people with IBD?”
Our objectives are to determine the effectiveness of
using IBD nurses to deliver the algorithm of care proposed
by NICE for people with FI, compared to provision of the
same information in a self-management booklet and to
obtain detailed qualitative feedback from patients and staff
on the best way of enabling health-seeking, the experience
of the intervention and suggestions for future service
development.
Trial design
This is a two-arm parallel group randomised controlled
trial (RCT) with 1:1 allocation intended to show super-
iority of IBD nurse intervention plus an information
booklet, compared with an information booklet alone.
The study has a total duration of 30 months.
Methods
Study setting
Six hospital centres with IBD clinics in metropolitan,
urban and rural locations in England are recruiting and
treating participants, in partnership with a Pragmatic
Clinical Trials Unit (PCTU) in London. A list of sites
can be obtained from the lead author.
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Eligibility criteria
The Screening Case Report Form (CRF) will be used to
conduct pre-registration evaluation of participants for
eligibility.
Inclusion criteria
 Proof of IBD diagnosis (record of diagnostic
endoscopy in patient notes).
 Between 18 and 80 years old
 No current flare-up of disease - stable disease and
treatment status (in remission) for the past 3
months confirmed by documented normal results
for inflammatory markers (C-reactive protein or
faecal calprotectin [FCP]) recorded within a 3-month
eligibility period; FCP tests to be repeated at
recruitment to confirm IBD is in remission if no
recent results documented
 Reporting FI at least once in the past year which is
limiting self-reported quality of life and activities
(determined by responses to survey above), enabling
inclusion of the majority of people with IBD-FI
whose quality of life is, in their own view, restricted
Exclusion criteria
 Current disease flare-up
 Course of specialist FI treatment in the past year
(e.g. biofeedback, tibial nerve stimulation). From our
previous work we hypothesise that this will be very
few potential participants [4]
 Previous major anal fistula surgery or current perianal
fistula (which can compromise anal sphincter function
and control, increasing the risk of FI)
 Current stoma (faeces will be diverted)
 Current participation in another trial
 Inability to give informed consent (for example,
due to reduced mental capacity)
 Inability to read or speak sufficient English to
understand study documents, procedures and
requirements.
Interventions
Group 1 (IBD nurse CONSULT +BOOKLET): will have
3–4 x 30-minute face-to-face sessions over 3 months with
an IBD specialist nurse specifically focusing on bowel con-
trol. Participants completing at least three sessions will be
considered to have completed the intervention. They will
also be given the self-management booklet and access to
all usual IBD care, including the routine local nurse-led
IBD helpline.
Booklet development
We have worked with four people with IBD-FI to oper-
ationalise the UK NICE guidance on FI [13, 19] as a book-
let for self-help for FI in IBD: Managing Incontinence in
Inflammatory Bowel Disease. It includes practical advice
on bowel habit, diet and fluids, anti-diarrhoeal medication,
bowel retraining, pelvic floor exercises, practical coping
and is based on our published advice for people with FI
[20, 21] adapted to be IBD-specific.
Training IBD nurses
One or two IBD nurse specialists at each centre
(maximum of 12 in total) will deliver the IBD nurse
intervention. An intensive 1-day scripted training
programme on managing FI will be delivered by two
members of the study team. A checklist for interven-
tion sessions included in the Group 1 Intervention
CRF will monitor fidelity to the content and we will
conduct two initial “test” sessions with each IBD
nurse to gauge competence and 3–4 follow-up visits
at random during patient consultations to gauge fidel-
ity to the intervention.
Group 2 (BOOKLET alone): will receive the same
booklet and access to usual IBD care as group 1. We
recognise the potential influence on usual care of train-
ing the IBD nurses to deliver the intervention. We will
emphasise during training the importance of trying not
to influence usual care for the booklet arm participants
and wherever feasible for another team member to see
these patients in consultations (teams are large enough
to accommodate this). In reality the IBD nurses are very
busy managing acute aspects of IBD and are unlikely to
have time to spontaneously provide more intensive input
for FI. Our interviews (below) will explore perceptions
of whether usual care was influenced by having the trial
in progress.
Withdrawal criteria
Participants have the right to withdraw from the study
at any time, despite having given consent to take part,
without having to give a reason for doing so. Their right
and access to their usual NHS treatment will not be
compromised in any way if they do withdraw. As indi-
cated on the Patient Consent Form and explained in the
Patient Information Sheet, all data collected before the
point of withdrawal will be retained and analysed unless
the patient specifically requests otherwise. We will ask
those who withdraw if their withdrawal is due to the
conditions of the study (i.e. too onerous/difficult to ad-
here to), seeking a simple yes/no answer. No further de-
tail will be sought. This information will help to place
any attrition in context and inform ongoing intervention
design beyond this study.
Strategies to improve adherence
No specific strategies will be employed. We will explore
perceived adherence and ease of complying with the ad-
vice in the nested qualitative study (below).
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Relevant concomitant care
Participants will have full access to usual NHS care for
IBD during the trial.
Study outcome measures
Data will be collected by a self-completed booklet of
questionnaires, given to the participant by a research
nurse not conducting the intervention. Study outcome
measures will be recorded at baseline and at 6 months
after randomisation.
Primary outcome measure
• The St Mark’s faecal incontinence score [22] (0–24
scale) at 6 months after randomisation, compared be-
tween the study groups, analysed as a continuous vari-
able. This is a widely used outcome measure in studies
of FI and a 3-point difference in score has been found to
be clinically relevant [23].
Secondary outcome measures
 ICIQ–IBD (condition-specific questionnaire for
symptoms and quality of life in IBD-FI) [10]
 Inflammatory bowel disease questionnaire [24] (the
most widely used condition-specific IBD quality-of-
life measure)
 Disease activity index to determine if disease activity
level has changed (Harvey Bradshaw index for
Crohn’s disease [25] and simple clinical colitis
activity index for ulcerative colitis [26], and medical
record of any escalation of treatment)
 MY-MOP [27] (generic tool: participants set two
goals for intervention, grading goals at baseline
and then re-scoring after intervention, giving an
individualised profile of the most bothersome
symptom, allowing analysis as a continuous
variable)
 EQ-5D-5 L [28] to enable calculation of quality-
adjusted life years (QALYS)
 Patient and NHS resource use for interventions
(time and consumables used, time off work, travel
costs)
 Study-specific tool: illness perceptions about FI and
its treatability
 Brief illness perception score [29] to determine if
illness perception influences completion and
response to intervention
 Study-specific tool: global perception of change,
which interventions participants engaged in (e.g. diet
change, pelvic floor exercises, use of anti-diarrhoeal
medication) and ease of compliance with advice,
satisfaction with intervention and qualitative
comments, any IBD flare-up (definition: need to
escalate or initiate medication/dose) during or since
intervention. This will enable insights into which
elements of the intervention are perceived by pa-
tients as most important.
A copy of trial outcome measures is available from the
lead author on request.
Participant timeline
The study flow chart is shown in Fig. 1.
Sample size for the trial
Sample size is based on a published response (improve-
ment) rate for conservative intervention for FI and a dif-
ference of 3 points in the St Mark’s FI score at 6 months
being considered to be of clinical significance to people
with FI but without IBD [23]. We will aim to randomise
186 people, with anticipated drop-out of 20 % (based on
our previous intervention studies and clinical experi-
ence), which will be sufficient to detect a difference of 3
points on the St Mark’s scale assuming a standard devi-
ation of 5, with a power of 90 %, using a 5 % significance
level (74 needed per arm, increased to 93 to allow for
drop-outs).
Recruitment
We will conduct an initial active case-finding phase
comprising a survey of the prevalence of FI among pa-
tients attending routine IBD clinics at the six centres.
We aim to include at least 2,000 people in this survey.
Respondents to this survey, who indicate a willingness
to participate in the trial, will be contacted by the re-
search nurse. Potential participants will be screened for
eligibility, in a telephone call. If eligible, patients will be
sent the Patient Information Sheet, re-contacted and, if
interested in participating, invited to attend an appoint-
ment with the research nurse to complete the Informed
Consent, Demographics and Randomisation CRF, and
the Baseline Measures CRF. Informed consent will be
obtained.
Demographic characteristics of age, type of IBD,
childbirth, history of perianal fistula and any related
surgery, other colorectal surgery, and current disease
activity and medications, will be recorded prior to
randomisation. The patient will then be entered into
the randomisation database and told whether they
are in group 1 (nurse + booklet) or group 2 (booklet
alone). Hospital consultants will be informed of the
patient’s participation in the study via an entry made
in the patient’s notes; the patient’s general practi-
tioner will be informed via a letter.
Assignment for intervention
Allocation
Consenting participants will be randomised by computer-
generated online block randomisation to either group 1
Norton et al. Trials  (2015) 16:444 Page 4 of 9
(IBD nurse CONSULT + BOOKLET) or group 2 (BOOK-
LET alone), stratified by centre and presence/absence of
an ileo-anal pouch (which is associated with a high rate of
FI), and using randomised blocks of two, four or six. Ran-
domisation will be designed and managed by the PCTU.
Blinding
Participating centres will be blinded to sequence alloca-
tion until they log into the system and confirm partici-
pant eligibility. Blinding of participants and IBD nurses
is not possible. The trial statistician will be blinded to
treatment allocation during data analysis. We have not
specified any permissible circumstances for unblinding
in this low-risk trial.
Data collection, management and analysis
Data collection
Data will be collected by a self-completed booklet of
questionnaires. Study outcome measures will be re-
corded at baseline (booklet contains 19 printed pages)
and at 6 months after randomisation (booklet contains
26 printed pages as it includes study-specific outcome
tools and health economic data). Acceptability of these
outcome booklets has been verified by our Patient and
Public Involvement (PPI) Group. Preliminary piloting
has found these take 20–30 minutes to complete and
our four PPI representatives have commented that this
is not unduly burdensome. Six months after randomisa-
tion, the outcome measures will be sent by post with
two postal reminders for non-responders after 3 and 5
weeks.
Data management
Electronic study data will be pseudonymised, stored on a
secure server and accessed via a secure network. Access
is restricted to authorised personnel only and via secure,
password-controlled, role-based access. All identifiable
data stored in paper files will be managed securely in
restricted-access, lockable containers at the individual par-
ticipating sites. All authors will have full access to the final
dataset. Following study closure, all data and study docu-
mentation will be archived at the sponsor site and held for
10 years, in accordance with sponsor requirements.
The PCTU standard operating procedures for data
entry, quality control, data extraction and database
freeze will be followed, and are available on request. All
outcome measures are self-reported and will be returned
to the recruitment site for inputting by the trial man-
ager. The data management plan (available on request
from the lead author), which includes source data verifi-
cation and instructions for data storage, will be followed.
After data cleaning, the database will be frozen and ana-
lysed by the study statistician, who will be blinded as to
group allocation.
Fig. 1 Patient flow diagram
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Outcome measures (see above) will be recorded at
baseline and at 6 months following randomisation.
There will be no additional follow-up. The study end-
point will be the date of database lock following data in-
putting, cleaning and checking. There will be no further
quantitative data collection after this point.
Statistical methods
Primary and secondary outcome measures at baseline
along with recruitment rates, session attendance, and
withdrawal from the intervention will be presented as
means and standard deviation for approximately nor-
mally distributed continuous variables, medians and
interquartile ranges for non-normally distributed vari-
ables, and frequencies and percentages for categorical
variables. Estimates of treatment effect on primary and
secondary outcomes at the follow-up assessments will
use an intention-to-treat (ITT) framework, implemented
using a regression model, adjusting for baseline values of
the outcome, centre, and presence of an ileo-anal pouch.
ITT analysis will include all participants with outcome
data regardless of adherence to the intervention. Where
participants wish to withdraw from the intervention, we
will attempt to retain them in the data collection, unless
they express a wish to be withdrawn completely.
Also reported:
1. Comparison between the groups on secondary
outcome measures, although the study is not
powered to detect significant differences.
2. Sub-group analysis, including any apparent
difference in response according to type of IBD
(Crohn’s vs. other forms of IBD), childbirth (any
vaginal delivery vs. none)
3. The impact of experiencing disease flare-up (defined
as needing to escalate or initiate medication doses)
on benefits of intervention
4. Health economic analysis (below)
5. Process data from study-specific questionnaire and
IBD nurse records on which interventions were used
6. Qualitative data (see below)
Health economic analysis
The health economics evaluation will estimate the costs
associated with the delivery of the nurse-led FI manage-
ment programme to patients with IBD, and compare the
use of health care resources by patients receiving the
two FI management interventions: (i) booklet plus nurse
consultations and (ii) booklet alone. The analysis will be
conducted from the perspective of the NHS and Per-
sonal Social Services. Economic evaluation methods will
adhere, as far as possible, to the NICE Guide to the
Methods of Technology Appraisal 2013 [30].
The cost of delivery of the nurse-led FI management
programme will include: the cost of booklet development
and production; the cost of training IBD nurses; the cost
of consultations with IBD nurses. In addition to the cost
of delivery of the FI management programme, the costs of
health care services use by participants will be studied.
These costs will cover primary care services including
consultations, medication, investigations and referrals to
secondary care. Secondary care services will include out-
patient appointments, inpatient episodes and accident
and emergency department (A&E) visits. A resource-
use questionnaire asking participants about their use
of health care services and medication has been de-
veloped using the online Database of Instruments for
Resource Use Measurement [31]. Primary and second-
ary care unit costs will be derived from the UK Unit
Costs of Health and Social Care [32]. The unit costs
for secondary care will be based on the UK National
Schedule of Reference Costs [33]. The unit costs for
medication will be obtained from the Prescription
Cost Analysis database [34]. Costs associated with the
two FI management strategies will be presented in a
disaggregated format with effectiveness outcomes
(cost-consequences analysis). The estimated mean
costs for each group will be presented alongside the
mean estimates of primary and secondary outcomes.
Monitoring
Study management and access to data
The trial sponsor is London North West Hospitals NHS
Trust, UK (contact Dr Alan Warnes: alan.warnes@nhs.
net). The sponsor will provide insurance and access to
compensation for participants who suffer harm.
The Trial Oversight Committee deliberates the prac-
tical and logistical aspects of the study. The committee
is comprised of all co-applicants (co-authors of this
manuscript). This committee will have access to the final
dataset with no restrictions.
The Trial Management Group oversees the study to en-
sure fidelity to PCTU, sponsor, Research Ethics Committee
and protocol requirements. The group is comprised of the
chief investigator (CI), the trial manager, statistician, data-
base manager and quality monitor, and a representative of
the sponsor.
The Trial Steering Committee provides independent
monitoring of the study, and is comprised of an inde-
pendent chair, statistician, clinician, trial manager and
patient representative. This committee also substitutes
for a Data Monitoring Committee in this low-risk study.
The Patient and Public Involvement Group, supported
by the trial manager, will contribute throughout the
study to the design of patient-facing materials, and to
analysis and report writing. It is comprised of a chair
and four members, all of whom are patients with IBD.
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Harms
This is a very low-risk study as no drug, medical device
or surgical intervention is being trialled. However, the
CI may take urgent safety measures to ensure the safety
and protection of the clinical trial subjects from any im-
mediate hazard to their health and safety.
The responsible medical consultant will be notified of
their patient’s participation in the study, and will also re-
ceive an instruction sheet which lists all expected ad-
verse events, and instructions to contact the CI in the
event of any unexpected, potentially related adverse
events. Expected potential adverse events for this study
are:
1. Flare-up of disease activity (score of 5 or more on
the Harvey Bradshaw index or the simple clinical
colitis activity index)
2. Some degree of emotional distress
All adverse events will be recorded in the Adverse
Events Log. Unexpected adverse events will be reported
to the sponsor and the Research Ethics Committee
within 24 hours.
Auditing
A trial monitor employed by the PCTU and independent
from the investigators and the sponsor will monitor sites
6-monthly and in any case where concerns are raised by
any member of the team.
Nested qualitative study
Participants consenting to the trial might be invited for
interview. They will have received information about the
interviews in the trial Patient Information Sheet. Separ-
ate informed consent will be sought for the face-to-face,
semi-structured interviews with a purposive sample of
approximately 20 participants (or until apparent data
saturation), ten from each arm of the RCT. The inter-
view sub-sample will include both genders, a range of
ages, both IBD diagnoses and those successful and not
successful in improving FI, to better understand patient
perspectives on the intervention.
All participating IBD nurses will also be interviewed to
understand their experience of delivering the interven-
tions and to inform future adaptation and delivery of the
intervention in clinical practice. A purposive sample of
ten clinicians (gastroenterologists and IBD nurses not
delivering the intervention) will be interviewed to ascer-
tain their views of the interventions and ease of incorp-
orating interventions for FI into routine IBD care. Four
IBD service managers will be interviewed for views on
incorporating a continence service into IBD services. All
staff will receive the Participant Information Sheet –
Staff Interviews. Consent will be obtained.
Qualitative analysis
Interviews will be digitally recorded, anonymised, and
professionally transcribed verbatim. Original audio files
and file transcripts will be stored on a secure server at
King’s College London in a protected file accessible only
by the trial manager. The transcriber will delete her copy
of each audio file once transcription is complete. Data
will be analysed using a pragmatic thematic analysis
[35]. Two researchers will code transcripts independ-
ently and then compare and refine resulting codes and
themes in discussion. The emergent themes will form
the basis of analytical interpretation.
Ethics
The CI has obtained approval from a recognised Research
Ethics Committee (National Research Ethics Committee
London-Hampstead, project reference 154290, approval
reference number: 15/LO/0051). The study will be con-
ducted in accordance with the recommendations for phy-
sicians involved in research on human subjects adopted
by the 18th World Medical Assembly, Helsinki 1964
(including later revisions), the UK Research Governance
Framework for Health and Social Care 2005 and subse-
quent amendments, Good Clinical Practice Guidelines
1996, and the UK Data Protection Act 1998. Important
protocol amendments will be communicated to the
Research Ethics Committee and study sponsor by the CI.
Consent
Potential participants will receive a full explanation of
the study, be given the patient information sheet and
have at least 24 hours to consider whether to take part.
Written consent will be secured from recruited partici-
pants by an appropriately trained research nurse or clin-
ician, or clinical trials practitioner, using the Patient
Consent Form (Additional file 1) during a baseline ap-
pointment prior to the patient entering the trial and be-
ing randomised. Separate informed consent will be taken
for interviews (see Additional file 2).
Confidentiality
The CI will preserve the confidentiality of participants
taking part in the study and will work in accordance
with the Data Protection Act 1998, NHS Code of Confi-
dentiality and any relevant NHS Trust organisational
policies and NHS Caldecott Principles.
Post-trial care
When the trial is completed, patients dissatisfied with
the outcome will be offered referral to specialist contin-
ence services for investigation and treatment (routine
NHS care). Booklet group participants will be offered
the opportunity to receive the IBD nurse + Booklet inter-
vention after completion of the outcome questionnaires at
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6 months post-randomisation, according to local capacity
to deliver. Numbers taking up referral or post-RCT inter-
vention will be monitored and outcome of this routine
specialised clinical care cohort will be assessed.
Dissemination
It is planned to publish the results of this study in a sci-
entific journal. Participants will be offered a lay summary
of results. The co-applicants will be authors of this
manuscript. There are no restrictions on publication of
results from the sponsor or funder.
Discussion
As FI is a potentially reversible symptom, with good evi-
dence for what works for FI in other people and strong
national guidance, there is potential to make a major dif-
ference to patients and produce high-quality evidence
which could be rolled out across the NHS at relatively
modest cost. It is important to clinicians as currently
they do not address the issue of FI in IBD and have the
potential to extend their services to address aspects that
bother patients in more holistic care than currently of-
fered. Current clinical services for IBD focus almost en-
tirely on treatment of active disease and gut inflammation,
with (to date) very limited attention to other symptoms
and problems which stop patients working, participating
in society and having a good quality of life. Our qualitative
work and data on which interventions patients engage in
and why will inform the way services are configured in the
future. With a growing number of people living with long-
term IBD there are many who could benefit from this
research.
Relatively few high-quality studies of conservative in-
terventions in inflammatory bowel disease have been
conducted. We have collaborated closely with patients
to design this study to meet their needs. Blinding to this
behavioural intervention is not possible, but we have se-
lected self-report outcome measures with a degree of
objectivity. There is genuine equipoise between the
booklet only and booklet plus nurse arms, and the study
will determine if additional support from a nurse is a
crucial element in implementing advice.
Trial registration
This trial is registered on the publicly accessible registry
(clinitrials.gov.uk: NCT02355834).
Trial status
This protocol (version 4.0, dated 8 April 2015) is that
approved by the Research Ethics Committee on 15 April
2015. Recruitment to the RCT commenced on 11 May
2015 and should complete by the end of February 2017.
The study report will be available at the end of 2017.
Reporting of this protocol conforms with the Spirit
checklist (www.spirit-statement.org/wp-content/uploads/
2013/01/SPIRIT-Checklist-download-8Jan13.pdf, accessed
05.10.15) as required by Trials (see Additional file 3).
Additional files
Additional file 1: Consent form for RCT. (PDF 121 kb)
Additional file 2: Consent form for interviews. (PDF 116 kb)
Additional file 3: Spirit checklist. (DOC 121 kb)
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